Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s40744-014-0002-7
Published Online: 2014-09-23
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bergman, Martin J.
Elkin, Eric P.
Ogale, Sarika
Kamath, Tripthi
Hamburger, Max I.